Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
31
OCGN Quote, Financials, Valuation and Earnings
Last price:
$0.77
Seasonality move
:
325.93%
Day range:
$0.73 - $0.80
52-week range:
$0.39 - $2.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
43.22x
P/B ratio:
5.55x
Volume:
21.6M
Avg. volume:
5M
1-year change:
103.6%
Market cap:
$225.6M
Revenue:
$6M
EPS (TTM):
-$0.18
Analysts' Opinion
-
Consensus RatingOcugen has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Ocugen has an estimated upside of 707.18% from its current price of $0.77.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.77.
Fair Value
-
According to the consensus of 0 analysts, Ocugen has 707.18% upside to fair value with a price target of -- per share.
OCGN vs. S&P 500
-
Over the past 5 trading days, Ocugen has underperformed the S&P 500 by -7.86% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ocugen does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ocugen revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Ocugen reported revenues of $1.1M.
Earnings Growth
-
Ocugen has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ocugen reported earnings per share of -$0.05.
Enterprise value:
189.8M
EV / Invested capital:
4.36x
Price / LTM sales:
43.22x
EV / EBIT:
--
EV / Revenue:
40.37x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.86x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-87.13%
Net Income Margin (TTM):
-1088.17%
Return On Equity:
-136.91%
Return On Invested Capital:
-127.27%
Operating Margin:
-1166.55%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $7.1M | $4.7M | $3.7M | $1.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$75.3M | -$82.4M | -$52.4M | -$12.4M | -$13.3M | |
| EBITDA | -$74.9M | -$81.7M | -$50.9M | -$12.3M | -$12.6M | |
| Diluted EPS | -$0.35 | -$0.33 | -$0.18 | -$0.05 | -$0.05 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $19.8M | $113.5M | $107.5M | $56.6M | $40.7M | |
| Total Assets | $20.5M | $116.3M | $116.2M | $74.7M | $61.9M | |
| Current Liabilities | $4.1M | $6.2M | $14.9M | $11.1M | $15.8M | |
| Total Liabilities | $6.1M | $9.2M | $20.9M | $16.3M | $21.3M | |
| Total Equity | $14.4M | $107.1M | $95.3M | $58.4M | $40.6M | |
| Total Debt | $3.2M | $1.7M | $2.3M | $2.8M | $2.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$56M | -$67.7M | -$43.1M | -$13.7M | -$11.3M | |
| Cash From Investing | -$1.9M | -$9.5M | -$6.1M | -$3.4M | -$507K | |
| Cash From Financing | $51.9M | $29M | $34.7M | -$35K | $34.8M | |
| Free Cash Flow | -$58.6M | -$77.4M | -$49.2M | -$17.1M | -$11.8M | |
OCGN
Sector
Market Cap
$225.6M
$44.6M
Price % of 52-Week High
36.78%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-13.06%
-0.68%
1-Year Price Total Return
103.6%
-29.09%
Beta (5-Year)
3.823
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.82
200-day SMA
Sell
Level
$1.30
Bollinger Bands (100)
Sell
Level
0.89 - 1.21
Chaikin Money Flow
Buy
Level
421.9M
20-day SMA
Sell
Level
$0.87
Relative Strength Index (RSI14)
Sell
Level
34.00
ADX Line
Buy
Level
0.17
Williams %R
Neutral
Level
-79.8636
50-day SMA
Sell
Level
$0.92
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
5B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.2917)
Sell
CA Score
(Annual)
Level (-3.109)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (7.1525)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Stock Forecast FAQ
In the current month, OCGN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OCGN average analyst price target in the past 3 months is --.
-
Where Will Ocugen Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ocugen share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Ocugen?
Analysts are divided on their view about Ocugen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ocugen is a Sell and believe this share price will drop from its current level to --.
-
What Is Ocugen's Price Target?
The price target for Ocugen over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OCGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ocugen is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OCGN?
You can purchase shares of Ocugen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ocugen shares.
-
What Is The Ocugen Share Price Today?
Ocugen was last trading at $0.77 per share. This represents the most recent stock quote for Ocugen. Yesterday, Ocugen closed at $0.77 per share.
-
How To Buy Ocugen Stock Online?
In order to purchase Ocugen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
